Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 146-153

  Kauffman, Raymond F ^a   Bensch, William R ^a   Roudebush, Roger E ^a   Cole, Harlan W ^a   Bean, James S ^a   Lynn Phillips, D ^a   Monroe, Amy ^a   Cullinan, George J ^a   Glasebrook, Andrew L ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; ETHINYLESTRADIOL; RALOXIFENE;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; HORMONE RECEPTOR INTERACTION; HYPOCHOLESTEROLEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; ORGAN SPECIFICITY; OVARIECTOMY; PIPERIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN;

EID: 8244264298     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. ANZANO, M. A., PEER, C. W., SMITH, J. M., MULLEN, L. T., SCHRADER, M. W., LOGSDON, D. L., DRIVER, C. L., BROWN, C. C., ROBERTS, A. B. AND SPORN, M. B.: Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88: 123-125, 1996.
2. BLACK, L. J., JONES, C. D. AND FALCONE, J. F.: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32: 1031-1036, 1983.
3. BLACK, L. J., SATO, M., ROWLEY, E. R., MAGEE, D. E., BEKELE, A., WILLIAMS, D. C., CULLINAN, G. J., BENDELE, R., KAUFFMAN, R. F., BENSCH, W. R., FROLIK, C. A., TERMINE, J. D. AND BRYANT, H. U.: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93: 63-69, 1994.
4. BROWN, M. S. AND GOLDSTEIN, J. L.: The estradiol-stimulated lipoprotein receptor of rat liver. J. Biol. Chem. 254: 11360-11366, 1980.
5. BRUNING, P. F., BONFRER, J. M. G., HART, A. A. M., DE JONG-BAKKER, M., LlNDERS, D, VAN LOON, J. AND NOOYEN, W. J.: Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer 58: 497-499, 1988.
6. BRYANT, H. U., MAGEE, D. E., COLE, H. W., CHANDRASECHAR, S., HSIUNG, H. M., HEIMAN, M. L. AND SATO, M.; Beneficial effects of ethynyl estradiol and raloxifene in the ovariectomized rat are dependent on an intact pituitary. J. Bone Miner. Res. 9: suppl. 1, S135, 1994.
7. CHAO, Y., WINDLER, E. E., CHEN, G. C. AND HAVEL, R. J.: Hepatic catabolism of rat and human lipoproteins in rata treated with 17-α-ethinyl estradiol. J. Biol. Chem. 254: 11360-11366, 1979.
8. CLEMENS, J. A., BENNETT, D. R., BLACK, L. J. AND JONES, C. D.: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32: 2869-2875, 1983.
9. COLDITZ, G. A., HANKINSON, S. E., HUNTER, D. J., WILLETT, W. C., MANSON, J. E., HENNEKENS, C., ROSNER, B. AND SPEIZER, F. E.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332: 1589-1593, 1995.
10. CYPRIANI, B., TABACIK, C. AND DESCOMPS, B.: Effect of estradiol and antiestrogens on cholesterol biosynthesis in hormone-dependent and -independent breast cancer cell lines. Biochim. Biophys. Acta 972: 167-178, 1988.
11. DRAPER, M. W., FLOWERS, D. E., HUSTER, W. J., NEILD, J. A., HARPER, K. D. AND ARNAUD, C.: A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11: 835-842, 1996.
12. DUNNETT, C. W.: A multiple comparison procedure for comparing several means with a control. J. Am. Stat. Assoc. 50: 1096-1121, 1955.
13. EVANS, G., BRYANT, H. U., MAGEE, D., SATO, M. AND TURNER, R. T.: The effects of raloxifene on tibia histomorphometry in ovariectomized rats, Endocrinology 134: 2283-2288, 1993.
14. FISHER, R. A.: The Design of Experiments. Oliver and Boyd Ltd., Edinburgh, 1949.
15. GOLD, E., STAPLEY, S. AND GOULDING, A.: Tamoxifen and nurethisterone: Effects on plasma cholesterol and total body calcium content in the estrogen-deficient rat. Horm. Metab. Res. 26: 100-103, 1994.
16. GOTFREDSEN, R., CHRISTIANSEN, C. AND PALSHOF, T.: The effect of tamoxifen on bone mineral content in pre-menopausal women with breast cancer. Cancer (Phila.) 53: 853-857, 1984.
17. GOTTARDIS, N. M. AND JORDAN, V. C.: Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47: 4020-4024, 1987.
18. GYLLING, H., MANTYLA, E. AND MIETTINEN, T. A.: Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis. Atherosclerosis 96: 245-247, 1992.
19. HAMMOND, C. B.: Women's concerns with hormone replacement therapy: Compliance issues. Fertil, Steril. 62: suppl. 2, 157S-160S, 1994.
20. HATCH, F. T. AND LEES, R. S.: Practical methods for plasma lipoprotein analysis. Adv. Lipid Res. 6: 1-68, 1968.
21. JUNES, C. D., JEVNIKAR, M. G., PIKE, A. J., PETERS, M. K., BLACK, L. J., THOMPSON, A. R., FALCONE, J. F. AND CLEMENS, J. A.: Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]-thien-3-yl || 4-[2-(1-piperidinyl)ethoxylphenyl] methanone hydrochloride (LY156768), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27: 1057-1066, 1984.
22. JORDAN, V. C.: Biochemical pharmacology of antiestrogen action. Pharmacol. Rev. 36:245-276, 1984.
23. KANNEL, W. B., HJORTLAND, M. C., MCNAMARA, P. M. AND GORDON, T.: Menopause and the risk of cardiovascular disease: The Framingham Study. Ann. Intern. Med. 85: 447-452, 1976.
24. KAUFFMAN, R. F. AND BRYANT, H. U.: Selective estrogen receptor modulators, Drug News Perspect. 8: 531-539, 1995.
25. MA, P. T. S., YAMAMOTO, T., GOLDSTEIN, J. L. AND BROWN, M. S.: Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17αethinyl estradiol. Proc. Natl. Acad. Sci. U.S.A. 83: 792-796, 1986.
26. McDONNELL, D. P., CLEMM, D. L., HERMANN, T., GOLDMAN, M. E. AND PIKE, J. W.: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens, Mol. Endocrinol. 9: 659-669, 1995.
27. MILLER, M. A., LIPPMAN, M. E. AND KATZENELLENBOGEN, B. S.: Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells. Cancer Res. 44: 5038-5045, 1983.
28. MOON, L. Y., WAKLEY, G. K. AND TURNER, R. T.: Dose-dependent effects of tamoxifen on long bones in growing rats: Influence of ovarian status. Endocrinology 129: 1568-1574, 1991.
29. RICHELSON, L. S., WAHNER, H. W., MELTON, L. J. 3D AND RIGGS, B. L.: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N. Engl. J. Med. 311: 1273-1275, 1984.
30. SATO, M., GLASEBROOK, A. L. AND BRYANT, H. U.: Raloxifene: A selective estrogen receptor modulator. J. Bone Miner. Metab. 12: suppl. 2, S9-S20, 1995.
31. STAELS, B., AUWERX, J., CHAN, L., VAN TOL., A., ROHSENEU, M. AND VERHOEVEN, G.: Influence of development, estrogens and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine. J. Lipid Res. 30: 1137-1145, 1989.
32. STEINBERG, M., TOLKSDORF, S. AND GORDON, A. S.; Relation of the adrenal and pituitary to the hypocholesterolemic effect of estrogen in rats, Endocrinology 81: 340-344, 1967.
33. THOMPSON, C., HUDSON, P. M. AND LUCIER, G. W.: Correlation of hepatic estrogen receptor concentrations and estrogen-mediated elevation of very low density lipoproteins. Endocrinology 112: 1389-1397, 1983.
34. TURNER, C. H., SATO, M. AND BRYANT, H. U.; Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135: 2001-2005, 1994.
35. VOIGT, L. F., WEISS, N. S., CHU, J., DALING, J. R., MCKNIGHT, B. AND VAN BELLE, G.: Progestagen supplementation of exogenous oestrogens and risk of endo- metrial cancer. Lancet 338: 274-277, 1991.
36. WAKELING, A. E., VALCACCIA, B., NEWBOULT, E. AND GREEN, L. R.: Non-steroidal antiestrogens: Receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J. Steroid Biochem. 20: 111-120, 1984.
37. WALSH, B. W., SCHIFF, I., ROSNER, B., GREENBERG, L., RAVNIKAR, V. AND SACKS, F. M.: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325: 1196-1204, 1991.
38. WEINSTEIN, I., WILCOX, H. G. AND HEIMBERG, M.: Effects of high-dose ethynylestradiol on serum concentrations and hepatic secretion of the very low density lipoprotein triacylglycerol cholesterol and apolipoprotein A-I in the rat. Biochim. Biophys. Acta 876: 450-459, 1986.
39. YANG, N. N., VENUGOPALAN, M., HARDIKAR, S. AND GLASEBROOK, A.; Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273: 1222-1225, 1996.